Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease

Surgical Infections
Therèse M DuaneDavid B Huang

Abstract

We evaluated drug efficacy and safety among patients with and without vascular disease who were treated with linezolid or vancomycin for a lower-extremity complicated skin and skin structure infection (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). We pooled data from two randomized clinical trials evaluating the efficacy and safety of linezolid 600 mg intravenously (IV) or orally every 12 h and vancomycin 15 mg/kg or 1 g IV every 12 h for the treatment of cSSSI caused by culture-proved MRSA. There were 477 patients for analysis. Among patients with vascular disease (linezolid n=139, vancomycin n=135), the clinical success rate was 80.4% and 66.7% (p=0.02) for patients treated with linezolid and vancomycin, respectively. Among patients without vascular disease (linezolid n=91, vancomycin n=112), the clinical success rate was 94.5% and 89.4%, respectively (p=0.24). Linezolid-treated patients had fewer IV catheter-site complications and less kidney impairment but more frequent thrombocytopenia than those who received vancomycin, regardless of the presence or absence of vascular disease. Linezolid is an effective treatment for patients with and without vascular disease who have a lower-extremity cSSSI caused ...Continue Reading

References

Jul 23, 1998·The Surgical Clinics of North America·D E FryM Langsfeld
May 17, 2001·Antimicrobial Agents and Chemotherapy·T GeeR Wise
Sep 26, 2001·Infectious Disease Clinics of North America·E L Pesanti
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A LipskyUNKNOWN Infectious Diseases Society of America
May 27, 2005·Antimicrobial Agents and Chemotherapy·John WeigeltUNKNOWN Linezolid CSSTI Study Group
May 27, 2005·Antimicrobial Agents and Chemotherapy·Pejman DehghanyarChristian Joukhadar
May 23, 2006·Diagnostic Microbiology and Infectious Disease·Paul B CorniaBenjamin A Lipsky
Jun 18, 2010·Surgical Infections·John A Weigelt
Dec 8, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Benjamin A LipskyDavid B Huang

❮ Previous
Next ❯

Citations

Nov 29, 2014·BMC Infectious Diseases·Cristina Vazquez-Guillamet, Marin H Kollef
Jul 23, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C EckmannS Haider
Jul 23, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M DrydenS Haider
Mar 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M BassettiM Wilcox
Apr 13, 2019·Pharmaceutical Statistics·Ping Gao, Katherine Odem-Davis
Feb 15, 2014·Current Opinion in Infectious Diseases·Deirdre J O'Brien, Ian M Gould

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
scrapings
amputation

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.